Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | DUT | P33316 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6722438 | 0.84 | ATM (0.38) | NPC1DUTALDH1A1MAPTMEN1 | |
| SCHEMBL6727003 | 0.82 | NPC1 (0.37) | NPC1DUTALDH1A1MAPTMEN1 | |
| SCHEMBL25344725 | 0.81 | NPC1 (0.38) | NPC1DUTALDH1A1MAPTMEN1 | |
| SCHEMBL25346003 | 0.81 | NPC1 (0.36) | NPC1DUTALDH1A1MAPTMEN1 | |
| SCHEMBL27384981 | 0.80 | ALDH1A1 (0.43) | ALDH1A1MAPTMEN1KMT2ATHRB | |
| SCHEMBL25345207 | 0.80 | NPC1 (0.35) | NPC1DUTALDH1A1MAPTMEN1 | |
| SCHEMBL25344963 | 0.80 | NPC1 (0.35) | NPC1DUTALDH1A1MAPTMEN1 | |
| SCHEMBL6726798 | 0.80 | NPC1 (0.40) | NPC1DUTALDH1A1MAPTMEN1 | |
| SCHEMBL6719796 | 0.80 | DUT (0.37) | NPC1DUTALDH1A1MAPTMEN1 | |
| SCHEMBL23415160 | 0.79 | DUT (0.36) | NPC1DUTALDH1A1MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744664-A2 | PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS | MyoKardia, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20240382486-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2024-11-21 | — | — | US | disclosed |
| US-RE50050-E1 | Pyrimidinedione compounds | MyoKardia, Inc. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20230165860-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230165860-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230165860-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2023-06-01 | — | — | US | disclosed |
| WO-2022032144-A1 | SUBSTRATE ADAPTOR INHIBITORS OF PRMT5 AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| US-20210346379-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2021-11-11 | — | — | US | disclosed |
| US-20210346379-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2021-11-11 | — | — | US | disclosed |
| US-20200297726-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2020-09-24 | — | — | US | disclosed |
| US-9181200-B2 | Pyrimidinedione compounds | MyoKardia, Inc. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140378464-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2014-12-25 | — | — | US | disclosed |
| US-20140378464-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2014-12-25 | — | — | US | disclosed |
| US-20140378464-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2014-12-25 | — | — | US | disclosed |
| WO-2014205223-A1 | PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS | MyoKardia, Inc. (US) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014205223-A1 | PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS | MyoKardia, Inc. (US) | 2014-12-24 | — | — | WO | disclosed |
| US-20130079323-A1 | GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| EP-2475666-A2 | GYRASE INHIBITORS | Trius Therapeutics, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-6673804-B1 | PREVENTING OR TREATING ARTHRITIS (PARTICULARLY OSTEOARTHRITIS) OR INHIBITING METASTASIS, INVASION OR GROWTH OF CANCER (PARTICULARLY BREAST CANCER) | SANKYO COMPANY, LIMITED (JP) | 2004-01-06 | — | — | US | disclosed |
| EP-1069110-A1 | SULFONAMIDE DERIVATIVES | Sankyo Company Limited (JP) | 2001-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346379-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | NPC1 2234/4885DUT 7/4885ALDH1A1 1556/4885 |
| US-20140378464-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | NPC1 2234/4885DUT 7/4885ALDH1A1 1556/4885 |
| US-20240382486-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | NPC1 2234/4885DUT 7/4885ALDH1A1 1556/4885 |
| US-20130079323-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | NPC1 2807/4885DUT 102/4885ALDH1A1 2837/4885 |
| US-20230165860-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | NPC1 2234/4885DUT 7/4885ALDH1A1 1556/4885 |
| US-20200297726-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | NPC1 2234/4885DUT 7/4885ALDH1A1 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.